{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:40:06Z","timestamp":1792604406315,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"DOI":"10.1007\/s43441-026-01066-z","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:03:53Z","timestamp":1792602233000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Pragmatic Implementation Framework for Phase 2 Trials with Invasive Endpoints: Estimands, Missing Outcomes, and Decision-Ready Evidence"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3320-4072","authenticated-orcid":false,"given":"Dang Anh","family":"Tuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"1066_CR1","unstructured":"International Council for Harmonisation (ICH). E9(R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials. https:\/\/database.ich.org\/sites\/default\/files\/E9-R1_Step4_Guideline_2019_1203.pdf (accessed 01 May, 2026)."},{"issue":"6","key":"1066_CR2","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/pst.2395","volume":"23","author":"A Fierenz","year":"2024","unstructured":"Fierenz A, Zapf A. Current developments of the estimand concept. Pharm Stat. 2024;23(6):864\u20139. https:\/\/doi.org\/10.1002\/pst.2395","journal-title":"Pharm Stat"},{"key":"1066_CR3","doi-asserted-by":"publisher","first-page":"e076316","DOI":"10.1136\/bmj-2023-076316","volume":"384","author":"BC Kahan","year":"2024","unstructured":"Kahan BC, Hindley J, Edwards M, Cro S, Morris TP. The estimands framework: a primer on the ICH E9(R1) addendum. BMJ. 2024;384:e076316. https:\/\/doi.org\/10.1136\/bmj-2023-076316.","journal-title":"BMJ"},{"key":"1066_CR4","doi-asserted-by":"publisher","unstructured":"Polverejan E, O\u2019Kelly M, Hefting N, Norton JD, Lim P, Walton MK. Defining Clinical Trial Estimands: A Practical Guide for Study Teams with Examples Based on a Psychiatric Disorder. Therapeutic Innov Regul Sci, 57, 5, pp. 911\u201339, 2023, https:\/\/doi.org\/10.1007\/s43441-023-00524-2","DOI":"10.1007\/s43441-023-00524-2"},{"key":"1066_CR5","volume-title":"The Prevention and Treatment of Missing Data in Clinical Trials","author":"NR Council","year":"2010","unstructured":"National Research Council. The Prevention and Treatment of Missing Data in Clinical Trials. Washington, DC: National Academies; 2010."},{"issue":"14","key":"1066_CR6","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1056\/NEJMsr1203730","volume":"367","author":"RJ Little","year":"2012","unstructured":"Little RJ, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367(14):1355\u201360. https:\/\/doi.org\/10.1056\/NEJMsr1203730.","journal-title":"N Engl J Med"},{"key":"1066_CR7","unstructured":"(2025). M11, ICH Harmonised Guideline M11: Structure and Content of Clinical Protocols. [Online] Available: https:\/\/database.ich.org\/sites\/default\/files\/ICH_Step4_M11_Final_TechnicalSpecification_2025_1119.pdf"},{"issue":"10489","key":"1066_CR8","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/S0140-6736(25)00672-5","volume":"405","author":"S Hopewell","year":"2025","unstructured":"Hopewell S, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. Lancet. 2025;405(10489):1633\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(25)00672-5.","journal-title":"Lancet"},{"issue":"10530","key":"1066_CR9","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/S0140-6736(25)02276-7","volume":"407","author":"M Noureddin","year":"2026","unstructured":"Noureddin M, et al. Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2026;407(10530):794\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(25)02276-7.","journal-title":"Lancet"},{"key":"1066_CR10","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/sim.8569","volume":"39","author":"S Cro","year":"2020","unstructured":"Cro S, Morris TP, Kenward MG, Carpenter JR. Sensitivity analysis for clinical trials with missing continuous outcome data using controlled multiple imputation: A practical guide. Stat Med. 2020;39:2815\u201342. https:\/\/doi.org\/10.1002\/sim.8569","journal-title":"Stat Med"},{"issue":"6","key":"1066_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/pst.1549","volume":"12","author":"B Ratitch","year":"2013","unstructured":"Ratitch B, O\u2019Kelly M, Tosiello R. Missing data in clinical trials: from clinical assumptions to statistical analysis using pattern mixture models. Pharm Stat. 2013;12(6):337\u201347. https:\/\/doi.org\/10.1002\/pst.1549","journal-title":"Pharm Stat"},{"key":"1066_CR12","doi-asserted-by":"publisher","unstructured":"White I, Joseph R, Best N. A causal modelling framework for reference-based imputation and tipping point analysis in clinical trials with quantitative outcome. J Biopharm Stat, 30, 2, pp. 334\u201350, 2020, https:\/\/doi.org\/10.1080\/10543406.2019.1684308","DOI":"10.1080\/10543406.2019.1684308"},{"key":"1066_CR13","doi-asserted-by":"publisher","unstructured":"White IR, Horton NJ. J. Carpenter, r. i. m. statistics, social, and S. J. Pocock, Strategy for intention to treat analysis in randomised trials with missing outcome data, BMJ, vol. 342, p. d40, 2011, https:\/\/doi.org\/10.1136\/bmj.d40","DOI":"10.1136\/bmj.d40"},{"key":"1066_CR14","doi-asserted-by":"publisher","unstructured":"White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med, 30, 4, pp. 377\u201399, 2011, https:\/\/doi.org\/10.1002\/sim.4067","DOI":"10.1002\/sim.4067"},{"key":"1066_CR15","doi-asserted-by":"publisher","unstructured":"Frewer P, Mitchell P, Watkins C, Matcham J. Decision-making in early clinical drug development. Pharm Stat, 15, 3, pp. 255\u201363, 2016, https:\/\/doi.org\/10.1002\/pst.1746","DOI":"10.1002\/pst.1746"},{"key":"1066_CR16","doi-asserted-by":"publisher","unstructured":"Huang B, Talukder E, Han L, Kuan P-F. Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint. J Biopharm Stat, 29, 1, pp. 189\u2013202, 2019, https:\/\/doi.org\/10.1080\/10543406.2018.1489400","DOI":"10.1080\/10543406.2018.1489400"},{"key":"1066_CR17","unstructured":"(2022). FDA-2016-D-4460, Multiple Endpoints in Clinical Trials: Guidance for Industry. [Online] Available: https:\/\/www.fda.gov\/media\/162416\/download"},{"issue":"4","key":"1066_CR18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0895-4356(00)00314-0","volume":"54","author":"R Bender","year":"2001","unstructured":"Bender R, Lange S. Adjusting for multiple testing\u2014when and how? J Clin Epidemiol. 2001;54(4):343\u20139. https:\/\/doi.org\/10.1016\/S0895-4356(00)00314-0.","journal-title":"J Clin Epidemiol"},{"key":"1066_CR19","doi-asserted-by":"publisher","unstructured":"Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. Stat Med, 28, 4, pp. 586\u2013604, 2009, https:\/\/doi.org\/10.1002\/sim.3495","DOI":"10.1002\/sim.3495"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01066-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01066-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01066-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:03:55Z","timestamp":1792602235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01066-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":19,"alternative-id":["1066"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-01066-z","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}